Ferro-Denk

Quick links to important sections

Ferro-Denk

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferro-Denk

What Type of Medicine is Ferro-Denk?

Ferro-Denk is a pharmaceutical preparation classified as an antianemic agent, primarily designed to address and supplement the body's store of iron. This classification reflects its role in correcting deficiencies related to low levels of hemoglobin and red blood cells. The preparation is utilized for the targeted treatment of iron scarcity, providing a concentrated, bioavailable form of the essential element. This pharmaceutical identity emphasizes its defined therapeutic use as a specialized iron treatment.


Composition and Form: The Role of Ferrous Fumarate

The core component of the medication is Ferrous Fumarate, a synthetic iron salt that delivers elemental iron in its bivalent (Fe²⁺) state. Iron salts are used for the formation and function of hemoglobin. Ferro-Denk is typically marketed by its manufacturer, Denk Pharma, and is supplied as a film-coated tablet designed for oral administration, offering a stable and standardized dose. The film-coating is a formulation feature intended to improve tolerability and enhance swallowability within the digestive system.


What is the General Purpose of Taking Ferro-Denk?

The general purpose of taking Ferro-Denk is iron supplementation to restore and maintain the body's iron reserves. Iron supplementation is a standard therapy for correcting iron deficiency. For instance, a common use scenario involves individuals needing to rebuild stores depleted due to chronic loss or increased physiological demands. By delivering the essential mineral, the medicine supports the biological process of oxygen transport throughout the body, which is necessary for maintaining cellular function and overall vitality.

Regulatory References

  1. Blood Disorders | MedlinePlus
  2. Iron - Health Professional Fact Sheet | NIH ODS
  3. Anaemia - World Health Organization (WHO)

What side effects are possible with Ferro-Denk?

Possible Side Effects and Safety Information

Ferro-Denk, which contains an iron salt (ferrous fumarate or similar iron forms), is generally well-tolerated when taken as directed. However, like all supplements, it can cause side effects, most commonly involving the gastrointestinal system.


Common Side Effects

The most frequent side effects of oral iron supplementation include:

  • Gastrointestinal discomfort: Nausea, vomiting, stomach cramps, or upset stomach.
  • Changes in bowel habits: Constipation or diarrhea.
  • Darkening of stools: Iron commonly causes stools to become dark or black in color. This is not typically harmful but can mask the appearance of internal bleeding, so any concerns should be discussed with a doctor.

Taking the supplement with a small amount of food can often help reduce stomach-related side effects, although this may slightly decrease iron absorption.


Important Safety Information and Warnings

1. Iron Overdose

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than six. It is critical to keep this product, and all iron supplements, out of the reach and sight of children. Symptoms of overdose may include severe stomach pain, bloody vomit, and circulatory collapse. Seek emergency medical attention immediately in case of suspected overdose.

2. Drug Interactions

Iron can interact with and reduce the absorption of certain medications, including some antibiotics (like tetracyclines and quinolones), thyroid hormones (like levothyroxine), and antacids. To avoid interactions, a healthcare professional should advise on the appropriate timing between taking Ferro-Denk and other medicines, often separating the doses by two to four hours.

3. Serious Allergic Reaction

Though rare, symptoms of a serious allergic reaction (anaphylaxis) require immediate medical attention. These signs include rash, itching, severe dizziness, swelling of the face, tongue, or throat, and trouble breathing.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of iron-containing products like Ferro-Denk requires immediate, urgent medical attention. Due to the serious risk of iron toxicity, this section provides essential information on recognizing an overdose and the required emergency actions.


Recognizing Iron Overdose

Symptoms of iron overdose can be severe and typically begin with acute gastrointestinal distress before potentially progressing to systemic toxicity. Initial documented presentations may include:

  • Severe stomach pain and/or cramping
  • Severe nausea and vomiting
  • Diarrhea
  • Cold or clammy skin
  • Blue-tinged lips or skin
  • Loss of consciousness or profound lethargy

Population-Specific Risk and Emergency Actions

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under the age of 6 and is considered a medical emergency in this population. Parents and caregivers must treat any suspected or accidental ingestion by a child as life-threatening.

If an overdose is suspected or if a child has accidentally swallowed the product, immediately:

  • Call a poison control center (Poison Help Line) or a doctor.
  • Seek emergency medical attention at the nearest emergency department.

Do not wait for symptoms to appear before seeking help, as iron toxicity can rapidly become severe and potentially fatal.

Therapeutic Uses of Ferro-Denk

What Ferro-Denk Treats: Main Uses and Benefits

Ferro-Denk is commonly used in clinical settings to provide supportive therapeutic benefit against the pronounced physical symptoms of iron deficiency anemia. It is considered relevant in contexts involving heightened systemic burden and is applied in clinical settings that involve acute or unstable symptom patterns. This category of medication is used for the treatment of iron deficiency.


Easing Symptoms of Iron Deficiency Anemia

The medication is applied across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance. It helps address symptom clusters that may become intense or disruptive, such as persistent fatigue, pallor, and general weakness, which create noticeable interference with daily functioning. The medication is commonly used across conditions presenting with acute episodes and relevant in conditions characterized by periods of heightened symptoms.

Quick Fact: Relevant for symptoms related to physical discomfort


Support for Acute or Heightened Symptom Phases

Ferro-Denk is relevant in contexts marked by increased discomfort or tension and is commonly used when short-term symptomatic assistance is needed to manage a condition characterized by periods of heightened symptoms. It is often used during phases when symptoms become more noticeable and may assist with maintaining functional stability. This provides support that helps ease the overall symptom burden and improves day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ferro-Denk — Official Regulatory Information

The eligibility profile for Ferro-Denk (Ferrous Fumarate) is determined exclusively by formal population rules and contraindications defined in government regulatory labeling.


Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Adults and Older Adults.
  • Populations for whom use is not recommended (if applicable): Children, as the tablet formulation is not intended for their treatment.
  • Populations for whom use is contraindicated: Patients with known Hypersensitivity to the active substance or excipients; those undergoing repeated blood transfusions.
  • Age-related eligibility rules: Approved for use in Adults; not intended for use in children.
  • Condition-specific eligibility rules: Contraindicated in the presence of Haemochromatosis or Haemosiderosis (iron overload); Active Peptic Ulcer; and chronic inflammatory bowel diseases such as Ulcerative Colitis.
  • Pregnancy and lactation eligibility status (if explicitly documented): Use can be used during both pregnancy and breast-feeding when clinically indicated.
  • Eligibility-related restrictions: Use requires caution in patients with a history of treated peptic ulceration or following a gastrectomy procedure.

Eligibility Classifications (High-Level)

  • Eligibility severity classification (as defined in official documents): Contraindicated (e.g., iron overload), Not Intended (pediatric use), and Use with Caution (history of ulcer).
  • Regulatory basis (EMA / FDA / etc.): Established based on official Prescribing Information and Summary of Product Characteristics.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing absolute exclusions for populations with pre-existing iron overload or active severe gastrointestinal disease. The profile is further structured by a clear age restriction and explicit permission for use during pregnancy and lactation when clinically required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ferro-Denk’s official interaction profile is rooted in a pharmacokinetic mechanism where the Ferrous Fumarate acts as a polyvalent cation, causing chelation in the gastrointestinal tract. This process results in altered absorption and final serum exposure for both the iron and numerous co-administered substances.

The iron cation formally decreases the absorption and systemic concentrations of several drugs, including Levothyroxine, Quinolone and Tetracycline Antibiotics, and certain antivirals such as Dolutegravir. The iron absorption itself is reduced when co-administered with Antacids, pH-altering agents, Calcium and Zinc supplements, and dietary items like dairy, tea, and coffee. Conversely, Vitamin C (Ascorbic Acid) is officially documented to increase iron absorption.

To manage these exposure changes, regulatory labeling mandates specific administration timing separation. For many interacting compounds, doses must be spaced by at least 2 to 6 hours to ensure sufficient drug absorption. Furthermore, combinations with agents like Dimercaprol and Baloxavir Marboxil are formally classified for avoidance due to the high risk of enhanced toxicity or severe loss of therapeutic efficacy, respectively. These constraints are integral to the drug's official regulatory documentation.

Mechanism of Action

Ferro-Denk provides elemental iron that interacts with fundamental biological systems. The mechanism is centered on supplying ferrous iron, which is absorbed via defined biological targets, such as the Divalent Metal Transporter 1 (DMT1), within the gastrointestinal pathway. Once absorbed, the iron binds to transferrin in the circulation, increasing the concentration of metal available for systemic distribution.

The primary downstream cascade occurs in the bone marrow's erythroid precursor cells, where the iron is an essential substrate required for the synthesis of heme. Heme is then incorporated into hemoglobin, which determines the blood's capacity for oxygen binding. Beyond oxygen carriage, the mechanism involves the engagement of the ferritin storage system and the role of iron as a cofactor in cellular processes, including electron transport in cytochromes.

Dosage and Administration Information

How to Use Ferro-Denk: Administration and Dosing Principles

Ferro-Denk, an iron preparation based on Ferrous Fumarate, is used strictly via the oral route as a film-coated tablet. The tablets are designed to be swallowed whole with an appropriate amount of water.

Standard dosing for established iron deficiency in adults typically involves a daily intake equivalent to 100 mg to 200 mg of elemental iron. The treatment is often taken once daily, although alternate-day dosing is a recognized option if the continuous daily regimen causes poor tolerability. For preventative use, such as during periods of increased demand, a lower daily elemental iron range is typically applied.

The timing of administration may be adjusted; while taking the tablet on an empty stomach is optimal for iron absorption, it can be taken with or immediately after food to improve comfort and tolerance.

The duration of use is defined by therapeutic goals. Treatment must generally continue for at least 3 months after the patient's hemoglobin concentration has normalized to ensure the replenishment of the body’s iron reserves. The total course of therapy for uncomplicated deficiency should generally not exceed six months. For pediatric populations, the tablet forms are typically not recommended, with liquid formulations often preferred for precise, weight-based administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Ferro-Denk

The information below summarizes the available research on the active ingredient, Ferrous Fumarate. The focus is on the types of studies conducted, the populations they included, and the aspects of iron deficiency that were monitored. This overview is based solely on the scientific evidence reported by regulatory bodies and in peer-reviewed literature.


Evidence for Use in Iron Deficiency Anemia (IDA)

Research examining the use of ferrous salts in people with Iron Deficiency Anemia (IDA) relies heavily on Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-analyses. Research was applied in studies examining outcomes related to systemic or functional imbalance. Research primarily included non-pregnant adults who had been diagnosed with IDA, meaning they had both low iron stores (ferritin) and low levels of hemoglobin.

Studies Evaluating Biomarkers and Symptom Reporting

Studies were conducted during periods of increased symptom activity and applied in trials assessing short-term or episodic symptom patterns. The core research examined changes in hematologic biomarkers, such as the concentration of Hemoglobin and levels of Serum Ferritin. Studies provide context on how changes were measured during the study period, describing how these markers evolved in the observed populations monitored during the study. Specifically, findings describe patterns observed in the studies related to the measurement of iron stores and the concentration of red blood cells. Studies also monitored patient-reported outcomes describing perceived discomfort, exploring how symptoms such as persistent fatigue and general weakness changed over the defined time intervals of the trial.


Evidence in Pregnancy-Related Iron Deficiency Anemia

The evidence base includes studies that evaluated the use of this type of iron salt in pregnant women diagnosed with iron deficiency anemia. The evidence base includes RCTs and cohort studies, relevant in research contexts involving fluctuating or unstable symptoms often associated with gestation.

Research examined the outcomes related to physical discomfort in these populations, with a focus on maternal hemoglobin and ferritin levels. Studies reported how these biomarkers evolved during the observation periods of the trial. Research also explored secondary outcomes, which were associated with delivery, such as the need for blood transfusions at birth. However, follow-up durations were limited, often covering only the period of the intervention during gestation.


What is Still Uncertain About the Research for Ferro-Denk

Evidence consistency varies across studies, and some key aspects of this treatment are not fully characterized by the research. The key limitations identified by the broader evidence landscape include that sample sizes were modest in some subgroups, and follow-up durations were limited in most trials. Data for certain age groups remain insufficient in the primary evidence base. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about the long-term patterns and outcomes related to iron supplementation.

Key Studies & References

  1. A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia
  2. Iron deficiency without anemia: indications for treatment - Gynecological and Reproductive Endocrinology & Metabolism (Review)
  3. Rewind: Treating iron-deficiency anemia in pregnancy: What are the most effective preparations? (Network Meta-analysis)

Frequently Asked Questions (FAQ)

Common questions about Ferro-Denk (FAQ)

Q: How quickly does Ferro-Denk start working?

A: Official documents describe that individuals may notice initial improvements in symptoms after about one week, with the intended effect typically observed within four weeks. However, regulatory guidance notes that the overall treatment time is longer, spanning several months, to ensure the body's iron reserves are fully restored.


Q: Can I take Ferro-Denk if I have a sensitive stomach?

A: Official patient information acknowledges that some people may experience stomach discomfort. Regulatory guidance indicates that taking the supplement with or immediately after food is a known method to improve tolerability, which may be beneficial for individuals with stomach sensitivity.


Q: Are there any common digestive issues while taking Ferro-Denk?

A: Regulatory documents list several frequently reported side effects related to the digestive system. These typically include stomach discomfort, nausea, vomiting, or changes in bowel habits such as constipation or diarrhea.


Q: Does Ferro-Denk affect how other medicines are absorbed?

A: Yes, the iron component in Ferro-Denk is known to chemically bind with certain other orally administered medicines in the stomach. Official documents describe that this binding process can reduce the absorption and overall systemic exposure of those other medications.


Q: What happens if I stop taking Ferro-Denk too soon?

A: Official guidance emphasizes that iron treatment needs to continue for several months after the patient's blood hemoglobin levels have returned to normal. Stopping earlier than the period advised may result in the body's iron reserves not being fully restored.


Q: Does Ferro-Denk contain any vitamins besides iron?

A: The core active ingredient in the product is Ferrous Fumarate, which serves as the iron source. Excipient lists in official documents often do not include other vitamins as co-active components, but it is important to check the specific product's patient leaflet, as non-active ingredients can vary by formulation.


Q: Can I take multivitamins with Ferro-Denk?

A: Many multivitamins contain minerals like calcium or zinc that are known to reduce the absorption of iron if taken at the same time. Official guidance describes that doses of iron and other supplements containing interacting minerals should typically be spaced apart to prevent reduced absorption.


Q: Is Ferro-Denk used for iron deficiency in the elderly?

A: The official regulatory eligibility profile covers Adults and Older Adults for the use of this medication when clinically needed.


Q: Do I need to change my diet while taking Ferro-Denk?

A: Regulatory documents describe that specific food items and beverages, such as dairy products, tea, coffee, and whole-grain cereals, can reduce the absorption of the iron. Therefore, official guidance suggests separating the time you take Ferro-Denk from the consumption of these items.


Q: Does Ferro-Denk contain any common allergens like gluten or lactose?

A: Official labeling lists all components, including non-active excipients. While this specific information can vary by manufacturer, many generic ferrous fumarate products are formulated to be free from common ingredients like gluten and lactose.


Q: Is Ferro-Denk suitable for vegetarian or vegan diets?

A: Official regulatory documents for some ferrous fumarate tablet formulations list Gelatin as one of the non-active ingredients. Because gelatin is generally derived from animal sources, this component is a factor that people following vegetarian or vegan diets should review when assessing suitability.


Q: Is Ferro-Denk the same as other products containing ferrous fumarate?

A: Ferro-Denk is classified by its active ingredient, Ferrous Fumarate, and its specific elemental iron content. Products with the same strength and active ingredient are considered therapeutically equivalent by regulatory standards, although non-active ingredients (excipients) used in the tablet formulation may differ between manufacturers.


Q: Can Ferro-Denk cause a metallic taste in the mouth?

A: While a metallic taste is not always listed as a frequent side effect in primary regulatory documents, scientific evidence describes that the chemical nature of iron salts, such as ferrous fumarate, can potentially result in this type of taste sensation.


Q: Is Ferro-Denk considered a prescription drug or over-the-counter?

A: Ferrous fumarate products are generally available for purchase over-the-counter (OTC) in pharmacies, depending on local regulations and specific product strength. The drug may also be obtained via prescription, depending on the specific product strength and the practices of the local health system.


Q: Are there specific symptoms that mean I should stop taking Ferro-Denk?

A: Patient information advises seeking immediate medical attention for signs of a severe allergic reaction or symptoms of overdose. For common or persistent side effects, official guidance is to consult a healthcare professional, but to continue taking the tablets unless otherwise advised by a doctor.


Q: Can Ferro-Denk be split or crushed?

A: According to the official administration instructions, the film-coated tablets are designed to be swallowed whole with a sufficient amount of water.


Q: Are there different strengths or versions of Ferro-Denk available?

A: Ferrous fumarate, the active ingredient, is manufactured in multiple strengths and may be available in various formulations, such as different tablet doses or liquid forms, depending on the country and the specific product line.


Q: Does official documentation mention long-term safety data for Ferro-Denk?

A: Official safety notes and regulatory documents advise that iron salts should be used cautiously on a long-term basis. Additionally, the available research base indicates that follow-up periods in key studies examining the treatment were limited.


Q: What warnings are listed regarding alcohol consumption while using Ferro-Denk?

A: Regulatory-cited information notes a moderate interaction between ferrous fumarate and alcohol, particularly concerning chronic alcohol use. The noted interaction involves chronic use and its effect on folic acid, which is often managed in clinical settings.


Q: Does the time of day matter when taking Ferro-Denk?

A: The time of day is not strictly mandated but can be adjusted based on individual priorities. Taking the tablet on an empty stomach is generally considered optimal for maximum absorption, while taking it with or after food is often chosen to improve stomach comfort.


Q: Are there any known interactions between Ferro-Denk and caffeine?

A: Yes, regulatory guidance explicitly notes that co-administering iron with caffeine-containing beverages, such as tea and coffee, can lead to a reduced absorption of iron.


Q: Do any official documents describe Ferro-Denk as causing headaches?

A: Headaches are not always listed as a frequent side effect in primary regulatory documents. However, some authoritative clinical resources recognize that headaches are among the possible adverse effects associated with oral iron therapy.


Q: Can people with kidney problems use Ferro-Denk?

A: Official documents and authoritative clinical information confirm that ferrous fumarate is used to treat iron deficiency anemia in patient populations, including those with chronic kidney disease.

How should Ferro-Denk be stored and disposed of?

How to Store and Dispose of Ferro-Denk?

Storing Ferro-Denk (Ferrous Fumarate) requires strict adherence to official regulatory conditions to maintain its quality and prevent accidental poisoning. The product must be stored below 30°C and must not be frozen. To protect the tablets from degradation, keep them in the original container, ensure it is tightly closed, and store in a dry place away from light.

Child-Safety Storage

It is mandatory to keep the medicine out of the sight and reach of children. Official labeling warns that the product contains iron and overdose may be fatal in children.

Disposal Instructions

Unused or expired Ferro-Denk must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of the medicine via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferro-Denk found in:

A-Z Index: